German BioNTech buys rival CureVac for $1.25 billion

Under the deal, which brings together two former competitors in the race to develop a COVID-19 vaccine, each CureVac share will be exchanged for approximately $5.46 in BioNTech American depositary shares (ADS), BioNTech said. The deal underscores BioNTech’s expensive long-term…








